

# GEORGIA MEDICAID FEE-FOR-SERVICE CYSTIC FIBROSIS, ORAL PA SUMMARY

Preferred	Non-Preferred
Bronchitol (mannitol)	N/A
Kalydeco (ivacaftor)	
Orkambi (lumacaftor/ivacaftor)	
Symdeko (tezacaftor/ivacaftor and ivacaftor)	
Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor)	

## **LENGTH OF AUTHORIZATION:** 1 year

**NOTE:** All agents require prior authorization (PA) and must be prescribed by or in consultation with a pulmonologist or specialist in cystic fibrosis.

#### PA CRITERIA:

### <u>Bronchitol</u>

❖ Approvable for members 18 years of age or older with a diagnosis of cystic fibrosis (CF) who have a forced expiratory volume in one second (FEV₁) % of predicted between 40% and 90%, have passed a Bronchitol Tolerance Test, have been prescribed a short-acting bronchodilator and have experienced an inadequate response, allergies, contraindications, drug-drug interactions or intolerable side effects with hypertonic saline and Pulmozyme

#### AND

❖ Must be used as add-on maintenance therapy to improve the member's pulmonary function.

#### Kalydeco

❖ Approvable for members 1 month of age or older with a diagnosis of cystic fibrosis who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to ivacaftor based on clinical evidence or *in vitro* assay data.

### Orkambi

❖ Approvable for members 1 year of age or older with a diagnosis of cystic fibrosis who are homozygous for the *F508del* mutation in the CFTR gene.

### <u>Symdeko</u>

❖ Approvable for members 6 years of age and older with a diagnosis of cystic fibrosis who are homozygous for the *F508del* mutation in the CFTR gene or who have at least one mutation in the CFTR gene that is responsive to tezacaftor/ivacaftor based on clinical evidence or *in vitro* assay data.

## **Trikafta**

❖ Approvable for members 2 years of age or older with a diagnosis of cystic fibrosis who have at least one *F508del* mutation in the CFTR gene or a mutation in the CFTR gene that is responsive based on *in vitro* data.



### **EXCEPTIONS:**

- Exceptions to these conditions of coverage are considered through the prior authorization process.
- The Prior Authorization process may be initiated by calling **OptumRx at 1-866-525-5827.**

### PREFERRED DRUG LIST:

• For online access to the Preferred Drug List (PDL), please go to <a href="http://dch.georgia.gov/preferred-drug-lists">http://dch.georgia.gov/preferred-drug-lists</a>.

### PA AND APPEAL PROCESS:

 For online access to the PA process, please go to <u>www.dch.georgia.gov/prior-authorization-process-and-criteria</u> and click on Prior Authorization (PA) Request Process Guide.

# **QUANTITY LEVEL LIMITATIONS:**

For online access to the current Quantity Level Limits (QLL), please go to
<u>www.mmis.georgia.gov/portal</u>, highlight Pharmacy and click on <u>Other Documents</u>, then
select the most recent quarters QLL list.